Incendia Therapeutics - About the company
Incendia Therapeutics is a series A company based in Boston (United States), founded in 2019 by Guy Travis Clifton. It operates as a Developer of immunotherapy for cancer treatment. Incendia Therapeutics has raised $65M in funding. The company has 147 active competitors, including 47 funded and 50 that have exited. Its top competitors include companies like Ascendis Pharma, Xencor and Rezolute.
Company Details
Developer of immunotherapy for cancer treatment. It offers PRTH-101which is a monoclonal antibody that binds to and inhibits Discoidin Domain Receptor 1 that stimulate immune-based antitumor activity for advanced or metastatic solid tumors.
- Website
- www.incendiatx.com
- Email ID
- *****@incendiatx.com
- Phone Number
- +1 **********
- Registered Address
- Cambridge, MA 02142
Key Metrics
Founded Year
2019
Location
Boston, United States
Stage
Series A
Total Funding
$65M in 1 round
Latest Funding Round
Investors
Ranked
64th among 147 active competitors
Employee Count
19 as on Sep 30, 2026
Similar Companies
Legal entities associated with Incendia Therapeutics
Incendia Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
PARTHENON THERAPEUTICS INC CIN: 84-3150200 , United States, Active | Sep 16, 2019 | - | 21 (As on Dec 31, 2022) | - |
Sign up to download Incendia Therapeutics' company profile
Incendia Therapeutics's funding and investors
Incendia Therapeutics has raised a total funding of $65M over 1 round. Incendia Therapeutics has 2 institutional investors.
Here is the list of recent funding rounds of Incendia Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 03, 2021 | 9418259 | Series A | 1480167 | 6418696 | 6350212 | 7843273 |
Access funding benchmarks and valuations. Sign up today!View details of Incendia Therapeutics's funding rounds and investors
Incendia Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Incendia Therapeutics is Guy Travis Clifton. Wendye R Robbins is the CEO of Incendia Therapeutics.
Here are the details of Incendia Therapeutics' key team members:
- Guy Travis Clifton: Co-Founder of Incendia Therapeutics. Contact Info: 1 email address
- Wendye R Robbins: Co-Founder & CEO of Incendia Therapeutics. Contact Info: 1 email address
View details of Incendia Therapeutics's Founder profiles and Board Members
Incendia Therapeutics' employee count trend
Incendia Therapeutics has 19 employees as of Sep 26. Here is Incendia Therapeutics's employee count trend over the years:
Uncover Incendia Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Incendia Therapeutics's Competitors and alternates
Top competitors of Incendia Therapeutics include Ascendis Pharma, Xencor and Rezolute. Here is the list of Top 10 competitors of Incendia Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Ascendis Pharma 2007, Hellerup (Denmark), Public | Integrated biopharmaceutical company to advance its pipeline of long-acting prodrug therapies | $109M | 67/100 | |
2nd | Xencor 1997, Monrovia (United States), Public | Engineering Antibodies to treat autoimmune disorders, asthma, allergic diseases and cancer | $7.6M | 66/100 | |
3rd | Rezolute 2012, Denver (United States), Public | Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI) | - | 66/100 | |
4th | Ultragenyx 2010, Novato (United States), Acquired | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 65/100 | |
5th |  Firefly Bio 2022, San Francisco (United States), Acquired | Developer of antibody drug conjugates for the treatment of cancer | $94M | 65/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 64/100 | |
7th |  Pyxis Oncology 2019, Boston (United States), Public | Developer of antibody therapeutics for treating cancer | $174M | 63/100 | |
8th | ADC Therapeutics 2011, Epalinges (Switzerland), Public | Developer of antibody-drug conjugates for the treatment of cancer indications | $816M | 62/100 | |
9th | Mereo BioPharma 2015, London (United Kingdom), Public | Developer of therapeutics for cancer and rare diseases | $119M | 60/100 | |
10th | Adcentrx Therapeutics 2021, San Diego (United States), Series A | Developer of next-generation targeted therapies for cancer | $101M | 59/100 | |
64th |  Incendia Therapeutics 2019, Boston (United States), Series A | Developer of immunotherapy for cancer treatment | $65M | 39/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Incendia Therapeutics's competitors? Click here to see the top ones
Incendia Therapeutics's Investments and acquisitions
Incendia Therapeutics has made no investments or acquisitions yet.
Reports related to Incendia Therapeutics
Here is the latest report on Incendia Therapeutics's sector:
News related to Incendia Therapeutics
Filter this list•
Incendia Therapeutics Appoints Renowned Biotechnology Investor and Entrepreneur Louis G. Lange, M.D., Ph.D., to Board of DirectorsBusiness Wire•Dec 11, 2024•Incendia Therapeutics
•
Incendia Therapeutics Appoints Bradford Smith as Chief Financial OfficerBusiness Wire•Dec 03, 2024•Incendia Therapeutics
•
DELFI Diagnostics Working with Incendia Therapeutics to Employ Advanced Treatment Monitoring Test in a Phase 1 Clinical TrialPR Newswire•Oct 28, 2024•Delfi Diagnostics, Incendia Therapeutics
•
Incendia Therapeutics Enrolls First Patient in Phase 1c Clinical Trial of PRTH-101, a Novel DDR1 InhibitorBusiness Wire•Sep 10, 2024•Incendia Therapeutics
•
Incendia Therapeutics Announces Upcoming Presentation with PathAI at the 2024 American Society of Clinical Oncology Annual MeetingBusiness Wire•May 24, 2024•Incendia Therapeutics, PathAI
•
Incendia Therapeutics Appoints Wendye Robbins, M.D., as Chief Executive Officer and Doses First Patient in Phase 1b Clinical Trial of PRTH-101, a Novel DDR1 InhibitorBusiness Wire•Nov 13, 2023•Incendia Therapeutics
•
Xtalpi And Parthenon Enter Into Ai-powered Antibody Discovery PartnershipPipelinereview•Sep 06, 2023•XtalPi, Incendia Therapeutics
•
Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded TumorsBusiness Wire•Jun 22, 2023•Incendia Therapeutics
•
Parthenon Therapeutics Announces Publication In Journal For Immunotherapy Of Cancer On The Role Of Immune Exclusion In CancerBusiness Wire•Jun 12, 2023•Incendia Therapeutics
•
Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid TumorsBusiness Wire•Apr 25, 2023•Incendia Therapeutics, Parthenon Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Incendia Therapeutics
Explore our recently published companies
- Moooi Gemaakt - Oosterhout based, 2026 founded, Unfunded company
- Aethelgard Marambio - 2010 founded, Unfunded company
- Accsysindia - Chennai based, 2018 founded, Unfunded company
- FBasket - Delhi based, 2026 founded, Unfunded company
- Asaan - Gurugram based, 2015 founded, Unfunded company
- Danae Project - Massa based, 2008 founded, Unfunded company
